GlassScriptPhysician profile
Juan Arciniega
NPI 1508153115
$3,631.40
in general payments reported to CMS, 2019-2025
24 companies · $62.13 in 2025
The $62.13 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $493 · 2021: $1,085 · 2022: $734 · 2023: $246 · 2024: $438 · 2025: $62.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $597.80 | 2019-2023 | One Series Ultra |
| Glaukos Corporation | $331.44 | 2021-2022 | |
| Allergan, INC. | $280.68 | 2021 | |
| Alcon Vision LLC | $239.15 | 2020-2025 | Rocklatan, Hydrus Microstent, Clareon |
| Rxsight INC | $234.27 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $218.90 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $213.38 | 2024 | Miebo, Ic-8 Apthera Iol, Envista Mx60 Iol |
| Eyevance Pharmaceuticals LLC | $195.59 | 2019 | |
| Eyepoint US, INC. | $187.45 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $155.50 | 2022 | |
| Biotissue Holdings INC. | $133.87 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $131.13 | 2020 | |
| Kala Pharmaceuticals, INC. | $122.78 | 2021 | |
| Novartis Pharmaceuticals Corporation | $116.08 | 2021-2023 | |
| Merz North America, INC. | $100.00 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $62.12 | 2024 | |
| Lombart Brothers, INC. | $60.27 | 2023 | Opd-III |
| Sight Sciences, INC. | $55.45 | 2021-2025 | Omni Surgical System |
| Amgen INC. | $55.32 | 2024 | Tepezza |
| Oyster Point Pharma, INC. | $53.40 | 2022-2023 | Tyrvaya |
| Merz Pharmaceuticals, LLC | $47.80 | 2022-2023 | Xeomin |
| Beaver-Visitec International, INC. | $14.20 | 2019 | |
| Aerie Pharmaceuticals, INC. | $13.05 | 2021 | |
| Shire North American Group INC | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Arciniega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.